JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120504

Flecainide, Sodium channel blocker

Be the first to review this product! Submit a review

|

(2 Publications)

MW 414.34 Da, Purity >99%. Sodium channel blocker. Class IC antiarrhythmic agent. Inhibits fast Na+ current in cardiac muscle in a use- and concentration-dependent manner. Also inhibits cardiac ryanodine receptors. Orally-active.

View Alternative Names

Aland island eye disease (Forsius Eriksson ocular albinism, ocular albinism type 2), CAC1C_HUMAN, CAC1D_HUMAN, CAC1F_HUMAN, CACH 2, CACH3, CACN 2, CACN4, CACNA 1D, CACNAF, CACNAF1, CACNL1A1, CACNL1A2, CCHL1A1, CCHL1A2, CDCD2, CMD1E, CMPD2, COD 3, CORDX, CORDX 3, CSNB2A, CSNBX 2, CaV1.2, Calcium channel, Calcium channel L type alpha 1 polypeptide isoform 1 cardiac muscle, Calcium channel L type alpha 1 polypeptide isoform 2, Calcium channel cardic dihydropyridine sensitive alpha 1 subunit, Calcium channel neuroendocrine/brain type alpha 1 subunit, Calcium channel voltage dependent L type alpha 1, Calcium channel voltage dependent L type alpha 1C subunit, Calcium channel voltage dependent L type alpha 1D subunit, Calcium channel voltage dependent L type alpha 1F subunit, Calcium channel voltage dependent alpha 1F subunit, Cardiac tetrodotoxin insensitive voltage dependent sodium channel alpha subunit, Cav1.3, Cav1.4, Cav1.4alpha1, DHPR alpha 1, DHPR alpha 1 subunit, Eag-related protein 1, Ether a go go related potassium channel protein, Ether-a-go-go-related gene potassium channel 1, Ether-a-go-go-related protein 1, H-ERG, HB 1, HB2, HBBD, HH1, ICCD, IVF, JM 8, JMC 8, KCD2, KCND2_HUMAN, KCNH2_HUMAN, KIAA1044, Kv11.1, L type, LQT 2, LQT3, LQT8, MGC119702, MGC119703, PASNA, PFHB1, Potassium channel HERG, Potassium voltage gated channel Shal related subfamily member 2, Potassium voltage gated channel subfamily H (eag related) member 2, Potassium voltage-gated channel subfamily D member 2, Potassium voltage-gated channel subfamily H member 2, RK 5, SANDD, SCN5A_HUMAN, SQT1, SSS1, Scn5a (gene name), Sodium channel protein cardiac muscle alpha subunit, Sodium channel protein cardiac muscle subunit alpha, Sodium channel protein type 5 subunit alpha, Sodium channel protein type V alpha subunit, Sodium channel protein type V subunit alpha, TS, VF1, Voltage dependent L type calcium channel alpha 1C subunit, Voltage ependent L ype calcium channel subunit alpha F, Voltage gated L type calcium channel Cav1.2 alpha 1 subunit, splice variant 10*, Voltage gated calcium channel alpha 1 subunit, Voltage gated calcium channel alpha 1F subunit, Voltage gated calcium channel alpha subunit Cav1.2, Voltage gated calcium channel alpha subunit Cav1.3, Voltage gated calcium channel subunit alpha Cav1.4, Voltage gated potassium channel Kv4.2, Voltage gated potassium channel, subfamily H, member 2, Voltage gated sodium channel alpha subunit Nav1.5, Voltage sensitive potassium channel, Voltage-dependent L-type calcium channel subunit alpha-1C, Voltage-dependent L-type calcium channel subunit alpha-1D, Voltage-gated calcium channel subunit alpha Cav1.2, Voltage-gated calcium channel subunit alpha Cav1.3, Voltage-gated potassium channel subunit Kv11.1, Voltage-gated potassium channel subunit Kv4.2, Voltage-gated sodium channel subunit alpha Nav1.5, alpha-1 polypeptide, cardiac muscle, eag homolog, hERG-1, isoform 1, isoform 2

1 Images
Chemical Structure - Flecainide, Sodium channel blocker (AB120504)
  • Chemical Structure

Lab

Chemical Structure - Flecainide, Sodium channel blocker (AB120504)

2D chemical structure image of ab120504, Flecainide, Sodium channel blocker

Key facts

CAS number

54143-55-4

Purity

>99%

Form

Solid

form

Molecular weight

414.34 Da

Molecular formula

C<sub>1</sub><sub>7</sub>H<sub>2</sub><sub>0</sub>F<sub>6</sub>N<sub>2</sub>O<sub>3</sub>

PubChem

3356

Nature

Synthetic

Solubility

Soluble in ethanol to 100 mM

Soluble in DMSO to 50 mM

Biochemical name

Flecainide

Biological description

Sodium channel blocker. Class IC antiarrhythmic agent. Inhibits fast Na+ current in cardiac muscle in a use- and concentration-dependent manner. Also inhibits cardiac ryanodine receptors. Orally-active.

Canonical smiles

C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F

InChi

InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)

InChiKey

DJBNUMBKLMJRSA-UHFFFAOYSA-N

IUPAC Name

N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide

style
left-column
style
left-column

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The target proteins CACNA1C Kv4.2/KCND2 Nav1.5/SCN5A H-ERG CaV1.3 and CACNA1F are important ion channels that facilitate the movement of ions such as calcium potassium and sodium across cell membranes. These channels play an important role in generating and regulating action potentials within various cell types most notably in cardiac tissue and neurons. CACNA1C also known as CaV1.2 has a molecular mass of approximately 240 kDa and is expressed widely including in the heart brain and skeletal muscle. Kv4.2/KCND2 and H-ERG part of the potassium channel family contribute to cell repolarization whereas Nav1.5/SCN5A a sodium channel initiates action potential in cardiac cells. CaV1.3 and CACNA1F are calcium channels that are important for synaptic transmission and are expressed predominantly in sensory cells of the eye which is essential for vision.
Biological function summary

These ion channels regulate cellular excitability and facilitate signal transmission. CACNA1C and its counterparts which are often part of larger channel complexes coordinate with accessory proteins to modulate channel activity. Kv4.2 participates in the rapid repolarization phase of the cardiac action potential whereas Nav1.5 provides the influx of sodium necessary for the depolarization phase. CaV1.3 and CACNA1F are integral to calcium ion influx that triggers synaptic vesicle release in auditory and retinal cells. These biological functions are critical for proper cardiac rhythm and neuronal communication.

Pathways

These ion channels are integral to the cardiac action potential pathway and calcium signaling pathway. CACNA1C is part of the L-type calcium current within these pathways. Kv4.2 and Nav1.5 are closely associated with the cardiac action potential pathway controlling heart rate and rhythmicity. H-ERG participates in cardiac repolarization and its dysfunction is linked to arrhythmogenic pathways. These pathways involve intricate interactions with other proteins like KCNQ1 and RyR2 which further mediate cardiac and neuronal excitability.

Mutations or dysfunction in these ion channels can lead to severe cardiac and neurological conditions. CACNA1C mutations are associated with Timothy syndrome characterized by long QT intervals in cardiac electrophysiology and has a relationship with the protein calmodulin in calcium regulation. Malfunctions in Nav1.5 are critically linked to Brugada syndrome a genetic condition that results in irregular heartbeats. H-ERG abnormalities are implicated in long QT syndrome impacting cardiac rhythm and this condition involves interactions with KCNQ1. These disorders emphasize the importance of normal channel function for maintaining cardiac and neurological health.
style
left-column
style
left-column

Product protocols

style
left-column

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in pharmacology 11:569489 PubMed33628168

2021

Identifying Drug Response by Combining Measurements of the Membrane Potential, the Cytosolic Calcium Concentration, and the Extracellular Potential in Microphysiological Systems.

Applications

Unspecified application

Species

Unspecified reactive species

Karoline Horgmo Jæger,Verena Charwat,Samuel Wall,Kevin E Healy,Aslak Tveito

Scientific reports 8:1153 PubMed29348631

2018

Dynamic all-optical drug screening on cardiac voltage-gated ion channels.

Applications

Unspecified application

Species

Unspecified reactive species

Jonas Streit,Sonja Kleinlogel
View all publications
style
left-column
style
left-column
style
right-column

Complementary Products

Biochemicals

AB120056

Staurosporine, Protein kinase inhibitor

Chemical Structure - Staurosporine, Protein kinase inhibitor (AB120056)

  • 0
  • 0
Primary Antibodies

AB208379

Alexa Fluor® 488 Anti-SNAP25 antibody [EP3274]

RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Alexa Fluor® 488 Anti-SNAP25 antibody [EP3274] (AB208379)

  • 0
  • 0
Primary Antibodies

AB270987

Anti-CACNA1C antibody [EPR24535-131]

20ul selling size|RabMAb|Recombinant

Western blot - Anti-CACNA1C antibody [EPR24535-131] (AB270987)

  • 0
  • 0
Biochemicals

AB120420

Buspirone hydrochloride, 5-HT1A agonist

Chemical Structure - Buspirone hydrochloride, 5-HT1A agonist (AB120420)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com